Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary

J Oncol Pract. 2018 Apr;14(4):247-249. doi: 10.1200/JOP.18.00005. Epub 2018 Mar 8.

Authors

Julie R Brahmer¹, Christina Lacchetti¹, John A Thompson¹

Affiliation

¹ Johns Hopkins Kimmel Cancer Center, Baltimore, MD; American Society of Clinical Oncology, Alexandria, VA; University of Washington; and Fred Hutchinson Cancer Research Center, Seattle, WA.

PMID: 29517954
DOI: 10.1200/JOP.18.00005

No abstract available

Publication types

Practice Guideline

MeSH terms

Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Agents, Immunological / therapeutic use
Biomarkers, Tumor
Disease Management
Drug-Related Side Effects and Adverse Reactions / diagnosis*
Drug-Related Side Effects and Adverse Reactions / etiology*
Drug-Related Side Effects and Adverse Reactions / therapy*
Humans
Molecular Targeted Therapy / adverse effects*
Neoplasms / complications*
Neoplasms / drug therapy
Neoplasms / immunology
Neoplasms / metabolism

Substances

Antineoplastic Agents, Immunological
Biomarkers, Tumor